Navigation Links
Baxa Corporation Signs Exclusive Distribution Agreement With Leading Pharmaceutical Corporation in People's Republic of China
Date:10/19/2009

ENGLEWOOD, Colo., Oct. 19 /PRNewswire/ -- Baxa Corporation, a US-based medical device company in Englewood, Colorado, has signed an exclusive four-year distribution agreement with SINOPHARM, a China National Pharmaceutical Foreign Trade Corporation, to promote sales of its products in China. While the agreement covers all Baxa products, the ExactaMix(TM) 2400 Automated Compounder and the Repeater(TM) Pharmacy Pump have been recognized as ones that will increase efficiency for the hospitals targeted by Baxa and SINOPHARM in the People's Republic of China (PRC). Due to their existing practice of manual preparation, the companies expect that more than 250 hospitals could benefit from the Baxa pharmacy automation equipment.

The partners anticipate that Baxa Corporation's expertise in automation could greatly improve the existing processes in Chinese hospitals - making their pharmacy operations more accurate, safe and efficient. "Baxa products are used all across the world every day by thousands of pharmacies. By entering the Chinese market, patients there will access the same outstanding quality that Baxa products have provided for 35 years in other parts of the world," states Phil Walsh, Baxa Director of International Sales.

"In China, the curtain has just been raised on the automation and digitization of the hospital pharmacy. Baxa products serve as an integral part for pharmacy automation," states Li Hai Bo, Medical Equipment Manager, SINOPHARM. "Parenteral nutrition is widely used in China," he continues, "however SINOPHARM believes that the current practice of manual preparation is inadequate and may not meet the varied needs of individual patients."

A key component of this partnership is the recent announcement of the China State Council to allocate 850 billion Yuan ($123 billion USD) to reform its medical and healthcare system. Technological advancement was cited as being vital to the plan's success in improving the quality of medical services to the country's 1.3 billion people.

Baxa Corporation was founded in 1975 by Brian Baldwin and Ronald Baxa. Through more than three decades of rapid growth and change in the healthcare industry, Baxa Corporation has become a leading global supplier of solutions for handling, measuring and administering fluid medications. In addition to its global headquarters in Englewood, CO, Baxa has subsidiaries and sales offices in Florida, Canada and the United Kingdom; direct representation within Europe and distribution partners worldwide.

About Baxa Corporation

Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for medication handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of medications. Key products include the PadLock® Set Saver, Rapid-Fill(TM) Automated Syringe Fillers, ExactaMed® Oral Dispensers, MicroFuse® Syringe Infusers, Repeater(TM) Pharmacy Pumps, the DoseEdge(TM) Dose Management System and ExactaMix(TM) Multi-Source Automated Compounders; used worldwide in hospitals and healthcare facilities. Its subsidiary FHT, Inc. produces the IntelliFill i.v. ® automation. Further information is available at www.baxa.com.

About SinoPHARM

Established in 1981, China National Pharmaceutical Foreign Trade Corporation (SINOPHARM Foreign Trade) is a wholly owned subsidiary of China National Pharmaceutical Group Corporation (SINOPHARM Group). SINOPHARM's core businesses are investment, import and export, and domestic distribution in pharmaceutical and relevant sections, including pharmaceutical R&D, consultation, bonded warehousing and other value-added services such as overseas pharmaceutical projects and domestic wholesale of pharmaceuticals, medical instruments and equipment. SINOPHARM keeps the country's medicine reserve and plays an important role in disaster and emergency relief and disease and plague prevention. For more information, visit http://www.sino-pharm.com.

    Contact:
    Marian Robinson, Vice President, Marketing
    Baxa Corporation:  800.567.2292 ext. 2157 or 303.617.2157
    Email:  marian.robinson@baxa.com

    Maggie Chamberlin Holben, APR
    Absolutely Public Relations: 303.984.9801 or 303.669.3558
    Email: maggie@absolutelypr.com

    Li Hai Bo, Medical Equipment Manager, Health Care Division
    SINOPHARM: +8610 82074502
    lihaibo@sinopharm.com

SOURCE Baxa Corporation


'/>"/>
SOURCE Baxa Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
5. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
6. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
10. Immunosyn Corporation Releases SF-1019 Study Results
11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
Breaking Medicine Technology:
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
(Date:6/24/2016)... ... ... recruitment firm Slone Partners is pleased to announce the placement of Suzanne ... of North American Capital Sales at HTG Molecular . , In ... commercialization of the HTG EdgeSeq system and associated reagents in North America. , Headquartered ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider ... and other difficult to transfect cells, announces its launch of the PluriQ™ G9™ ... Editing System is a complete system for culturing and transfecting human pluripotent ...
Breaking Medicine News(10 mins):